Vol. 21/No. 15

A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.

Investigators will pit 2 PD-1/PD-L1–pathway agents against each other in a bid to determine which therapy can confer the greatest survival benefit in patients with PD-L1–high, advanced non–small cell lung cancer.

Immunotherapy use is associated with a higher risk for hospitalization and severe coronavirus disease 2019 infection in patients with cancer and the novel respiratory virus.

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

A panel of experts in breast cancer discuss the emergence of alpelisib, review data from the BYLieve trial, discuss the role of everolimus, and review the emergence of oral taxanes.

Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

Tanios S. Bekaii-Saab, MD, discusses how the field of gastrointestinal cancers is gaining ground with regard to the development of targeted and immunotherapy agents.

Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.

The coronavirus disease 2019 pandemic has raised the public profile of experts in infectious disease, epidemiology, and public health.